Cantor Fitzgerald
Cantor Fitzgerald is a leading brokerage service for Wall Street's fixed income inter-dealer community. Cantor is a recognized leader in the specialized areas of equity and fixed income capital markets, offering an impressive array of products and services to more than 5000 institutional clients around the world.
Cantor suffered a devastating loss on September 11, 2001, when the World Trade Center terrorist attacks claimed the lives of 658 of the company's 960 New York-based employees.
Howard W. Lutnick is the company's Chairman and CEO.
-
Cantor Sees 'Blockbuster Potential' In Aerie Pharma's (AERI) Rocklatan Script Data
-
Aerie Pharmaceuticals to Present at the Cantor Fitzgerald 2018 Global Healthcare Conference
-
Aerie Pharma (AERI) PT Raised to $86 at Cantor Fitzgerald
-
Aerie Pharma (AERI) Prices $75M Common Share Offering
-
Aerie Pharmaceuticals Announces Pricing of Public Offering of Common Stock
-
Aerie Pharma (AERI) to Offer $75M in Common Stock
-
Aerie Pharmaceuticals Announces Public Offering of Common Stock
-
Aerie Pharma (AERI) PT Raised to $77 at Cantor Fitzgerald following FDA approval of Rhopressa
-
Aerie Pharma (AERI) PT Raised to $69 at Cantor Fitzgerald
-
Aerie Pharm (AERI): No Surprises within Rhopressa Briefing Documents - Cantor Fitzgerald
-
Aerie Pharmaceuticals to Present at Two Investor Conferences in September
-
Aerie Pharma (AERI): Mercury 1 Data Drives PT Increase - Cantor
-
Aerie Pharma (AERI) Prices $75M Common Stock Offering at $53.75/Share; $50M in Common Stock Sold Through ATM Program
-
Aerie Pharmaceuticals Raises $125 Million in ATM Sales and Upsized Follow-On Offering
-
Aerie Pharma (AERI) Commences Public Offering of Common Stock
-
Aerie Pharmaceuticals Announces Public Offering of Common Stock
-
Cantor Fitzgerald Reiterates Overweight on Aerie Pharma (AERI) Following Announced Safety and Efficacy Results
-
Aerie Pharma (AERI) PT Raised to $56 at Cantor Fitzgerald
-
Aerie Pharma (AERI) Updates on Outstanding Shares, Cash Balance
-
Notable 52-Week Highs and Lows 9/16: (INTC) (AERI) (CRUS) High; (NVAX) (CXRX) (CSIQ) Low
-
Aerie Pharma (AERI) Prices Larger $75M Stock Offering at $29.50/Share
-
Aerie Pharmaceuticals Raises $125 Million in Public Offerings
-
Aerie Pharma (AERI) Announces $50M Common Stock Offering
-
Aerie Pharmaceuticals Announces Public Offering of Common Stock
-
Unusual 11 Mid-Day Movers 9/15: (AERI) (CLBS) (CBR) Higher; (UUUU) (ACST) (UWN) Lower
-
Aerie Pharma (AERI) PT Raised to $50 at Cantor Fitzgerald
-
Aerie Pharma (AERI) Enters $50M Equity Offering Sales Agreement
-
Aerie Pharmaceuticals to Present at Cantor Fitzgerald's 2nd Annual Healthcare Conference
-
Cantor Fitzgerald Starts Aerie Pharma (AERI) at Buy
-
Aerie Pharma (AERI) PT Raised to $40 at Cantor Fitzgerald
-
Aerie Pharmaceuticals to Present at the Cantor Fitzgerald 2015 Healthcare Conference
-
Aerie Pharma (AEIR) PT Doubled to $30 at Cantor Fitzgerald
-
Cantor Fitzgerald Upgrades Aerie Pharma (AERI) to Buy
-
Cantor Fitzgerald Downgrades Aerie Pharma (AERI) to Hold
-
Cantor Fitzgerald Starts Aerie Pharma (AERI) at Buy

